The NVX-CoV2373 (Novavax) vaccine against COVID-19 is protein-based and consists of a recombinant SARS-CoV-2 spike protein nanoparticle administered as a co-formulation with the adjuvant MartrixTM The vaccine received WHO Emergency Use Listing (EUL) in December 2021. The WHO EUL process evaluates the quality of manufacturing along with safety and efficacy of the vaccine. Like all other EUL vaccines, Novavax COVID-19 vaccine is safe and highly effective in preventing severe disease and hospitalization due to COVID-19. This vaccine is recommended for people aged 12 and above.

In Europe, the vaccine is manufactured under the tradename Nuvaxovid; in India, the vaccine is manufactured by the Serum Institute of India under the trade name Covovax.

Strategic Advisory Group of Experts on Immunization (SAGE) interim recommendations for use of COVID-19 vaccines:

https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/covid-19-materials